- Home
- EQR vs TEVA Comparison
EQR vs TEVA Comparison
Compare EQR & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | TEVA |
|---|---|---|
| Founded | 1993 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 30.2B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | EQR | TEVA |
|---|---|---|
| Price | $61.50 | $28.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $70.00 | $27.00 |
| AVG Volume (30 Days) | 2.1M | ★ 11.4M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ 24.49 | N/A |
| EPS | ★ 3.03 | 0.62 |
| Revenue | $3,078,827,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $5.06 | $4.74 |
| Revenue Next Year | $3.55 | $0.48 |
| P/E Ratio | ★ $20.13 | $46.12 |
| Revenue Growth | ★ 4.69 | 0.02 |
| 52 Week Low | $58.38 | $12.47 |
| 52 Week High | $75.86 | $28.68 |
Technical Indicators
Market Signals| Indicator | EQR | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 80.93 |
| Support Level | $61.02 | $24.01 |
| Resistance Level | $62.42 | $26.96 |
| Average True Range (ATR) | 0.90 | 0.68 |
| MACD | 0.26 | 0.19 |
| Stochastic Oscillator | 62.17 | 94.65 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.